This could, ultimately, be massive. Because to detect early stage ovarian cancer routinely would mean screening ALL women from about 20 to 75+, much like cervical screening, but in ovarian, you'd most likely need to test annually (not 5 yearly as for cervical cancer screening currently). BUT those buying shares today will need prolonged patience even if everything rolls smoothly and positively from here with no major hurdles to overcome (not all that likely as these things go). Specificity will be a question that will need a good to great answer - many adenocarcinomas share markers and they also share markers with other types of normal cells. So how specific this is to ovarian cancer will be an issue. That said, CA125 also lights up other normal cells types - you just don't see a lot of normal cell antigens in blood unless there's a cancer, and that's why at present, CA125 only really picks up latter stages (III, IV).

I was working in this field in the 1980s, specifically on monoclonal antibodies as markers for ovarian cancer, which tells you just how much and how long research has been going on targeting ovarian cancer. We had an similar antibody to CA125 (different antibody but same result - this was in the early days of CA125, and if anything, we had more data), but in those days, Australia did not have any ability to commercialize antibody tests.